Pulmonology
Lung Cancer
More in Lung Cancer
Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone
Oct 10, 2024
EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy
Sep 25, 2024
Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy
Sep 09, 2024
In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity
Aug 22, 2024
0.75
CME Credits